THOMAS KOSTEN to Delayed-Action Preparations
This is a "connection" page, showing publications THOMAS KOSTEN has written about Delayed-Action Preparations.
Connection Strength
0.533
-
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
Score: 0.184
-
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Addict Behav. 2020 12; 111:106538.
Score: 0.164
-
Pharmacotherapeutic environments for substance use disorders. Am J Drug Alcohol Abuse. 2007; 33(5):627-9.
Score: 0.064
-
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug Alcohol Depend. 2018 06 01; 187:171-178.
Score: 0.035
-
Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial. Medicine (Baltimore). 2018 Jan; 97(2):e9567.
Score: 0.035
-
Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. J Neuropsychiatry Clin Neurosci. 1997; 9(1):29-36.
Score: 0.032
-
Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict. 2008 Jul-Aug; 17(4):287-92.
Score: 0.018